We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AmerisourceBergen Corporation reported first-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.18 surpassing the Zacks Consensus Estimate of $1.94 by 12.4%. The bottom line also improved 23.9% year over year.
The better-than-expected bottom-line performance can be attributed to higher adjusted operating income.
Revenue Details
Revenues increased 9.7% to $52.52 billion in the reported quarter. Further, the top line beat the Zacks Consensus Estimate by 3.8%.
Segmental Analysis
Pharmaceutical Distribution Segment
Revenues at this segment totaled $50.49 billion, reflecting an increase of 9.7% on a year-over-year basis on the back of higher volume related to growth of some of its largest customers and continued strength in specialty product sales.
Segmental operating income was $496.1 million, up 26.6% year over year. Increase in gross profit resulting from revenue growth contributed to the upside.
AmerisourceBergen Corporation Price, Consensus and EPS Surprise
This segment includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Veterinary Supply.
Revenues at this segment were $2.05 billion, up 11.1% year over year. The upside was driven by growth across all three operating segments.
Operating income in the segment was $121.6 million in the quarter, up 16.4% year over year primarily due to growth in World Courier and MWI.
Margin Analysis
In the quarter under review, AmerisourceBergen reported adjusted gross profit of $1.43 billion, up 14.8% on a year-over-year basis. As a percentage of revenues, adjusted gross margin was 2.7% in the quarter, up 10 basis points (bps) a year-over-year basis.
The company reported adjusted operating income of $616.9 million, up 24.6% year over year. As a percentage of revenues, adjusted operating margin was 1.2% in the quarter, which expanded 20 bps from the year-ago quarter.
Fiscal 2021 Guidance Updated
AmerisourceBergen has updated its fiscal 2021 outlook, indicating sustained solid performance and solid execution. It is important to note here that the outlook does not take into account any contribution from the Alliance Healthcare buyout or any incremental growth resulting from the expanded U.S. partnership announced in January 2021.
Adjusted EPS is now estimated to be $8.40-$8.60 (up from the prior-guided range of $8.25-$8.50). The Zacks Consensus Estimate currently stands at $8.37.
The company estimates revenue growth in the high-single-digit percent range (up from the prior mid-single-digit percent range).
Adjusted operating income is now projected to grow in high-single-digit percent range (up from the prior mid-single-digit percent range).
Operating income at Pharmaceutical Distribution Services segment is now anticipated to improve in high-single-digit percent range (up from the prior mid-single-digit percent range).
For the Other segment, the metric is estimated to grow in the mid-to-high single digit percent range (up from the previous mid-single-digit percent range).
Adjusted free cash flow is estimated to be around $1.5 billion.
The company anticipates adjusted effective tax rate to be 21-22%.
Adjusted operating expenses is projected to increase in the mid-to-high-single digit percent range (widened from the previous mid-single-digit percent range).
Summing Up
AmerisourceBergen exited the fiscal first quarter on a strong note, wherein both earnings and revenues beat the consensus mark. The company continues to gain from its Pharmaceutical segment and World Courier business, which have been generating substantial profits for quite some time. Moreover, the company witnessed increase in gross profit in the quarter under review. Also, expansion in both gross and operating margins is a positive.
However, the company faces other headwinds like conversion of branded drugs and lower price generics. Cut-throat competition in the MedTech space also remains a concern.
Zacks Rank
Currently, AmerisourceBergen carries a Zacks Rank #3 (Hold).
PerkinElmer reported fourth-quarter 2020 adjusted EPS of $3.96, which beat the Zacks Consensus Estimate of $3.61 per share by 9.7%. Revenues of $1.36 billion surpassed the consensus mark by 7.7%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss per share of 2 cents. Revenues of $72.8 million beat the consensus mark by 8%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
AmerisourceBergen (ABC) Q1 Earnings & Revenues Beat Estimates
AmerisourceBergen Corporation reported first-quarter fiscal 2021 adjusted earnings per share (EPS) of $2.18 surpassing the Zacks Consensus Estimate of $1.94 by 12.4%. The bottom line also improved 23.9% year over year.
The better-than-expected bottom-line performance can be attributed to higher adjusted operating income.
Revenue Details
Revenues increased 9.7% to $52.52 billion in the reported quarter. Further, the top line beat the Zacks Consensus Estimate by 3.8%.
Segmental Analysis
Pharmaceutical Distribution Segment
Revenues at this segment totaled $50.49 billion, reflecting an increase of 9.7% on a year-over-year basis on the back of higher volume related to growth of some of its largest customers and continued strength in specialty product sales.
Segmental operating income was $496.1 million, up 26.6% year over year. Increase in gross profit resulting from revenue growth contributed to the upside.
AmerisourceBergen Corporation Price, Consensus and EPS Surprise
AmerisourceBergen Corporation price-consensus-eps-surprise-chart | AmerisourceBergen Corporation Quote
Other Segment
This segment includes AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Veterinary Supply.
Revenues at this segment were $2.05 billion, up 11.1% year over year. The upside was driven by growth across all three operating segments.
Operating income in the segment was $121.6 million in the quarter, up 16.4% year over year primarily due to growth in World Courier and MWI.
Margin Analysis
In the quarter under review, AmerisourceBergen reported adjusted gross profit of $1.43 billion, up 14.8% on a year-over-year basis. As a percentage of revenues, adjusted gross margin was 2.7% in the quarter, up 10 basis points (bps) a year-over-year basis.
The company reported adjusted operating income of $616.9 million, up 24.6% year over year. As a percentage of revenues, adjusted operating margin was 1.2% in the quarter, which expanded 20 bps from the year-ago quarter.
Fiscal 2021 Guidance Updated
AmerisourceBergen has updated its fiscal 2021 outlook, indicating sustained solid performance and solid execution. It is important to note here that the outlook does not take into account any contribution from the Alliance Healthcare buyout or any incremental growth resulting from the expanded U.S. partnership announced in January 2021.
Adjusted EPS is now estimated to be $8.40-$8.60 (up from the prior-guided range of $8.25-$8.50). The Zacks Consensus Estimate currently stands at $8.37.
The company estimates revenue growth in the high-single-digit percent range (up from the prior mid-single-digit percent range).
Adjusted operating income is now projected to grow in high-single-digit percent range (up from the prior mid-single-digit percent range).
Operating income at Pharmaceutical Distribution Services segment is now anticipated to improve in high-single-digit percent range (up from the prior mid-single-digit percent range).
For the Other segment, the metric is estimated to grow in the mid-to-high single digit percent range (up from the previous mid-single-digit percent range).
Adjusted free cash flow is estimated to be around $1.5 billion.
The company anticipates adjusted effective tax rate to be 21-22%.
Adjusted operating expenses is projected to increase in the mid-to-high-single digit percent range (widened from the previous mid-single-digit percent range).
Summing Up
AmerisourceBergen exited the fiscal first quarter on a strong note, wherein both earnings and revenues beat the consensus mark. The company continues to gain from its Pharmaceutical segment and World Courier business, which have been generating substantial profits for quite some time. Moreover, the company witnessed increase in gross profit in the quarter under review. Also, expansion in both gross and operating margins is a positive.
However, the company faces other headwinds like conversion of branded drugs and lower price generics. Cut-throat competition in the MedTech space also remains a concern.
Zacks Rank
Currently, AmerisourceBergen carries a Zacks Rank #3 (Hold).
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks in the broader medical space that have already announced their quarterly results are PerkinElmer, Inc. , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
PerkinElmer reported fourth-quarter 2020 adjusted EPS of $3.96, which beat the Zacks Consensus Estimate of $3.61 per share by 9.7%. Revenues of $1.36 billion surpassed the consensus mark by 7.7%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny against the Zacks Consensus Estimate of a loss per share of 2 cents. Revenues of $72.8 million beat the consensus mark by 8%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>